Atrial Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Biovalve Implantation

University of Turku850 enrolled

Overview

The primary purpose of the FIN-bioAVR registry is to assess the incidence of AF, strokes and major bleeding events in patients undergoing aortic valve replacement. This retrospective multicenter registry will include 850 patients with aortic valve replacement using bioprosthesis.

Study Type

OBSERVATIONAL

Enrollment

850

Conditions

Atrial Fibrillation Stroke Transient Ischemic Attack Bleeding Aortic Stenosis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients undergoing aortic valve bioprosthesis implantation Exclusion Criteria: * mechanical heart valves in any position

Locations (1)

Turku University Hospital

Turku, Finland

Outcomes

Primary Outcomes

Stroke

Time frame: 10 years

Mortality

Time frame: 10 years

atrial fibrillation

Time frame: 10 years

major bleeding

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.